$10.11
3.27% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$10.00
+3.33 49.93% 1M
+0.37 3.84% 6M
+2.27 29.37% YTD
-5.87 36.99% 1Y
-10.08 50.20% 3Y
-31.94 76.16% 5Y
-20.45 67.16% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.21 2.15%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $501.60m
Enterprise Value $367.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.34
P/S ratio (TTM) P/S ratio 3.20
P/B ratio (TTM) P/B ratio 1.83
Revenue growth (TTM) Revenue growth 80.70%
Revenue (TTM) Revenue $156.72m
EBIT (operating result TTM) EBIT $-157.36m
Free Cash Flow (TTM) Free Cash Flow $-86.94m
Cash position $267.87m
EPS (TTM) EPS $-3.14
P/E forward 10.14
P/S forward 1.58
EV/Sales forward 1.16
Short interest 12.54%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
92%
Hold
8%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
157 157
81% 81%
100%
- Direct Costs 49 49
11% 11%
31%
108 108
237% 237%
69%
- Selling and Administrative Expenses 59 59
13% 13%
37%
- Research and Development Expense 191 191
10% 10%
122%
-141 -141
43% 43%
-90%
- Depreciation and Amortization 16 16
8% 8%
10%
EBIT (Operating Income) EBIT -157 -157
40% 40%
-100%
Net Profit -158 -158
39% 39%
-101%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
one day ago
$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie ROCKVILLE, Md. , May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to...
Neutral
PRNewsWire
7 days ago
PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Neutral
Seeking Alpha
8 days ago
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chief Medical Officer Mitch Chan - CFO Conference Call Participants Mani Foroohar - Leerink Partners Gena Wang - Barclays Judah Frommer - Morgan Stanley Annabel Samimy - Stifel Paul Choi - Goldman Sach...
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 353
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today